The company's proprietary immunotherapy platform, Vigil, uses a patient's tumor-related antigens to train the immune system to attack cancer cells. Vigil has shown positive survival benefits in a randomized controlled clinical study and can be used to treat multiple cancer types. Gradalis is preparing for a Phase 3 registration trial in patients with ovarian cancer and has also shown positive signals of activity in multiple tumor types in Phase 1 trials.